The vascular endothelium
========================

The endothelium has an important role in maintaining vascular homeostasis. Although once considered simply as a semipermeable membrane, endothelial cells transduce a wide range of physiological stimuli, and in response, produce a variety of signalling molecules that exert autocrine and paracrine effects. The endothelium can therefore be considered as an important endocrine organ ([@b137]; [@b136]), and is responsible for maintaining vasomotor tone, hemostasis and thrombosis, inflammatory processes, platelet and leucocyte vessel-wall interactions, and controlling vascular permeability. The equilibrium between vasodilatation and vasoconstriction in regional vascular beds is largely controlled by the interaction between endothelium-derived vasoactive mediators and the vascular smooth muscle layer. Endothelial nitric oxide (NO), produced by constitutive activity of nitric oxide synthase (eNOS) ([@b116]), is a potent vasodilator and one of the most important regulators of vascular tone. In addition, NO is antiatherogenic, inhibiting platelet aggregation, smooth muscle proliferation, expression of adhesion molecules, and neutrophil aggregation ([@b137]; [@b136]). Arterial endothelial dysfunction is a key, early, and potentially reversible, event in the process of atherogenesis and is characterised by impaired NO bioavailability ([@b49]; [@b112]; [@b12]). Endothelial dysfunction causes impaired vasomotor responses to various neurohumoral stimuli which may contribute to transient myocardial ischemia, plaque rupture, thrombosis, and myocardial infarction ([@b80]). Endothelial dysfunction has so far been described in association with many established cardiovascular risk factors such as active and passive smoking, hypertension, hypercholesterolemia, obesity, and type II diabetes ([@b84]; [@b2]; [@b132]; [@b45]; [@b151]; [@b64]; [@b150]). The extent of endothelial dysfunction and vasomotor responsiveness correlates with the rate of progression of atherosclerosis and cardiovascular events ([@b115]; [@b148]). As such, endothelial function has importance, not only in determining predisposition to atherosclerotic disease, but also in determining prognosis in clinically affected patients.

Clinical assessment of endothelial function
===========================================

Endothelial function can be measured in a variety of ways using invasive and noninvasive techniques in the coronary and peripheral circulation. The clinical examination of endothelial function involves assessing the ability of the endothelium to release NO in response to various exogenous and endogenous stimuli. The quantity of NO released from endothelial cells determines the degree of vasodilatation detected in clinical studies, and thus arterial "health". [@b74] initially tested this concept by infusing acetylcholine into coronary arteries at angiography and measuring subsequent changes in arterial diameter. In healthy arteries, infusion of acetylcholine caused vasodilation, whereas vasoconstriction occurred in the presence of a damaged endothelial lining. Further evidence that the observed vasodilation was secondary to NO release was derived from studies which blocked dilatation using inhibitors of the L-arginine-NO pathway ([@b51]; [@b70]). Subsequent studies using vasoactive pharmacological and physiological agents have confirmed differences in dilatation and endothelial responsiveness between healthy vessels and atherosclerotic vessels ([@b44]; [@b158]).

Coronary angiography
--------------------

### Methods of assessment

Quantitative coronary artery angiography of the left anterior descending artery and intracoronary doppler techniques have been applied to measure coronary artery vaso-responsiveness in response to endothelium-dependent agonists such as bradykinin and mechanical stimuli such as increased flow. Quantitative angiography can assess coronary arterial luminal diameter following cardiac catheterization, whilst doppler probes evaluate blood flow velocity in response to infusion of vasoactive agents ([@b46]).

The integrity of coronary arteries has recently been evaluated angiographically via stimulation of the sympathetic nervous system using exercise and cold pressor tests. Sympathetic neuronal stimulation using cold pressor testing induces vasodilatation in healthy vasculature and vasoconstriction in proatherogenic disease states and atherosclerotic coronary arteries ([@b160]; [@b5]; [@b96]).

Although the coronary angiography technique is undoubtedly a useful tool for assessing vascular risk, widespread use is not practical. Coronary angiography is invasive and unsuitable for studying early preclinical atherosclerosis in asymptomatic subjects, or for the serial evaluation of vascular physiology in response to potential antiatherogenic strategies. Furthermore, its use is limited as a consequence of serious adverse reactions reported following the intracoronary infusion of acetylcholine at angiography ([@b131]).

### Association with coronary artery disease and atherosclerotic risk factors

Impaired vascular reactivity in the coronary artery circulation is associated with traditional coronary risk factors such as type 2 diabetes, insulin resistance, hypertension, and dyslipidemia ([@b96]; [@b28]; [@b91]), even in the absence of clinically overt atherosclerotic lesions. Impaired vascular reactivity may also serve as an index integrating the overall stress imposed by coronary risk factors ([@b143]). Coronary endothelial vasodilator dysfunction persists after angiographically significant coronary atherosclerotic plaque is evident and has been shown to predict long-term disease progression and cardiovascular event rates in patients at risk of coronary disease ([@b115]). However, disease modifying agents which reduce cholesterol and exhibit antioxidant qualities improve coronary artery endothelium-dependent dilatation ([@b2]; [@b132]) and may reflect the cardioprotective qualities of these agents.

Flow-mediated dilatation
------------------------

### Method of assessment

A noninvasive technique using high-resolution ultrasound to overcome the practical constraints of invasive coronary artery testing has been developed to assess endothelial function in the peripheral circulation ([@b19]). Using this technique, changes in brachial artery diameter are measured by following the endothelium-dependent stimulus of increased blood flow and may be compared with changes in vessel diameter following the oral administration of endothelium-independent agonists such as glyceryl trinitrate (GTN) ([@b19]). Since endothelial dysfunction is a generalized systemic process, it occurs in both the coronary and systemic circulation ([@b2]). Indeed, a close relationship has been demonstrated between vasodilator responses in the brachial artery and those in the coronary circulation ([@b2]; [@b81]). The sensitivity of the original technique developed by [@b19] has been improved by using a validated computerized vessel wall tracking system (Vadirec Medical Systems® \[[@b108]\]) to follow changes in brachial artery diameter throughout the cardiac cycle.

Many wall tracking systems have been developed to determine flow-mediated dilatation (FMD). One such system comprises an adapted duplex colour flow echo machine, giving high axial resolution ([@b108]). With this technique, the brachial artery is identified using an ultrasound transducer with a stand-off device containing ultrasound coupling gel placed between the transducer and the arm to prevent compression of the anterior wall of the artery. Vessel wall movements are tracked using the stored radio frequency signals to produce displacement waveforms of the anterior and posterior walls together with the distension waveform (diameter change as a function of time \[[@b53]\]). The distension waveform allows measurement of end-diastolic diameter for each beat, providing a theoretical resolution of 3 m. Forearm blood flow is measured throughout the study using a continuous wave doppler probe positioned over the brachial artery ([@b122]). Once baseline measurements of brachial artery diameter are established, a cuff placed at the wrist is inflated to suprasystolic pressure, causing relative hand ischemia. Release of the occluding cuff results in reactive hand hyperemia and an associated increase in blood flow through the brachial artery, which induces shear stress on the arterial wall and provides a stimulus for endothelium-dependent dilatation. Similar measurements can also be made using a NO donor, eg, glyceryl trinitrate (GTN) for an assessment of endothelial-independent vasodilatation ([@b19]).

A degree of investigator expertise is required to determine brachial artery vasodilation using ultrasonography and no consensus exists regarding the degree of vasodilation which should be expected in individuals with healthy endothelial function ([@b35]). Significant changes in brachial artery reactivity have been reported within healthy subjects throughout the course of a day when measured by the same operators, suggesting that variability occurs between morning and evening measurements, in addition to variability between subjects examined on different days ([@b32]). However, this is disputed by others who have carefully controlled for confounding factors ([@b128]). Despite this, FMD will continue to be an extensively used technique for assessing endothelial function. Improvements in available equipment and operator expertise will reduce variability in results.

### Association with coronary artery disease and atherosclerotic risk factors

The FMD technique is now one of the most widely used noninvasive methods of assessing endothelial function and closely correlates with cardiovascular risk ([@b65]). Impaired FMD is described in insulin resistant states and type 2 diabetes, dyslipidemia, hypertension, end stage renal disease, and smoking ([@b159]; [@b34]; [@b54]; [@b129]). Subsequently, FMD has been used extensively to assess the potential antiatherogenic qualities of treatment options, and continues to be indispensable in determining endothelial integrity.

Carotid intimamedial thickness
------------------------------

### Method of assessment

Another noninvasive method of assessing subclinical atherosclerosis involves measurements of carotid intimamedia thickness (IMT) with high resolution B-mode ultrasonography. This is a well established technique which has been extensively used to estimate coronary artery events and the extent of established atherosclerosis in central and peripheral vasculature ([@b17]), with early increases in IMT possibly reflecting adaptation to elevated intravascular shear stress ([@b16]). As a noninvasive imaging technique, quantitative carotid IMT is versatile for use in large populations with minimal risk to subjects ([@b9]). However, accurate measurements, particularly of the near wall, require a high level of technical expertise. Consequently, some authors suggest the administration of contrast media during the examination period ([@b76]; [@b79]).

A variety of techniques have been used in the determination of carotid IMT. Measurements of the common carotid, internal carotid, and carotid bifurcation are all technically acceptable, including combination measurements of 12 carotid arterial sites, eg, using Meijer\'s Arch ([@b15]). In view of the diversity and lack of uniformity in determining carotid IMT, meta-analysis suggests that circumferential scanning of the carotid artery and calculation of the mean maximum carotid IMT provides a more accurate measurement of carotid atherosclerosis ([@b15]). However, all sites of carotid IMT measurement appear to have equivalent value in predicting future coronary artery events ([@b56]).

### Association with coronary artery disease and atherosclerotic risk factors

Carotid IMT correlates with cardiovascular risk factors such as the 'metabolic syndrome' ([@b83]), insulin resistance in type 1 and 2 diabetics ([@b41]; [@b119]), microalbuminuria ([@b57]), hypercholesterolemia ([@b147]), and atherogenesis ([@b114]).

Carotid IMT and the progression of IMT correlates well with cardiovascular and cerebrovascular end-points ([@b16]; [@b52]; [@b99]). However, although extensive data supports the use of carotid IMT as a predictor of cardiovascular risk, endothelial dysfunction manifesting as impaired brachial artery reactivity may be an earlier predictor of coronary artery disease, with increased carotid IMT being evident at a later stage in the process of atherogenesis ([@b42]).

Cardiovascular risk and vascular stiffness
==========================================

Large artery stiffness
----------------------

Arteriosclerosis is an integral part of the aging process ([@b106]) and is now also recognised as an important and independent risk factor for cardiovascular disease ([@b7]). As a result of vascular stiffening, the diastolic blood pressure decreases and pulse pressure widens, as occurs with advancing age ([@b39]). Consequently, brachial artery pulse pressure is a surrogate marker of vascular stiffness and is used to determine cardiovascular risk in normotensive and hypertensive subjects ([@b11], [@b10]; [@b38]), having a higher predictive value of cardiovascular risk than mean arterial blood pressure ([@b33]; [@b87]). Isolated systolic hypertension and elevated pulse pressure have also been identified as a major cardiovascular risk factor in the Systolic Hypertension in the Elderly Programme and the Systolic Hypertension in Europe trial ([@b40]).

Confirming the association between pulse pressure and cardiovascular risk, [@b107] demonstrated a direct correlation between aortic pulse pressure, measured with intra-aortic balloons at coronary angiography, and the extent of atherosclerotic disease. Wave reflection within the vascular tree leads to a higher pulse pressure in central vessels than in the periphery ([@b105]; [@b93], [@b94]). The resulting increase in left ventricular after-load increases myocardial oxygen consumption and promotes left ventricular hypertrophy. In addition, increasing systolic pressure elevates arterial wall circumferential stress and predisposes to atherosclerotic plaque generation. Left ventricular hypertrophy that arises from increased aortic systolic pressure ([@b66]) predisposes to coronary artery disease ([@b77]), cerebrovascular events ([@b60]), and is an independent predictor of cardiovascular mortality ([@b72]). Furthermore, increased arterial stiffening has also been demonstrated in subjects with increased cardiovascular risk including diabetes mellitus ([@b144], [@b113]), hypertension ([@b85], [@b6]), hypercholesterolemia ([@b29], [@b43]), and end stage renal disease ([@b13]).

Regulation of large artery stiffness
------------------------------------

Elastin and collagen are the major determinants of large artery stiffness, with smooth muscle originally thought to play a minor role ([@b154]). Advancing age causes gradual destruction in arterial wall elasticity, with increasing demands placed on the collagenous element ([@b103]; [@b8]). This redistribution of the heterogeneous element in the vascular wall can be triggered by endothelial dysfunction ([@b95]). However, recent work has highlighted the importance of smooth muscle in determining vessel stiffening. Vasoconstrictors such as noradrenaline can increase vascular stiffness and dilators such as hydrallazine and sodium nitroprusside have the opposite effect ([@b94]). Such vasoactive pharmacological agents can alter vessel diameter by up to 30%, independent of changes in peripheral resistance or blood pressure ([@b67]), demonstrating the important dynamic contribution of vascular smooth muscle to large vessel stiffness.

Whilst NO profoundly alters basal arterial tone, its effect on arterial stiffness remains unclear. However, the acute administration of a NO donor such as GTN produces changes in the peripheral pressure pulse that are consistent with a reduction in arterial stiffness ([@b25]). β-adrenergic drugs, in particular albuterol, act via the L-arginine-NO pathway to stimulate NO release and cause vasodilatation in resistance arteries ([@b18]; [@b31]) via their action on β~2~-adrenoreceptors. β~2~-agonists have therefore been used to evaluate endothelial integrity in healthy controls ([@b48]).

Clinical assessment of arterial stiffness
=========================================

Pulse wave analysis and pulse wave velocity
-------------------------------------------

### Method of assessment

The peripheral pressure waveform can be useful in determining cardiovascular risk. However, an adequate assessment of central arterial pressure waveforms cannot be determined from peripheral pulse wave analysis (PWA) because changes in vessel stiffening throughout the vascular tree causes location-dependent changes in the pressure waveform. In addition, central arterial waveforms will be influenced by the reflective wave phenomenon as described by [@b94]. The systolic waveform leaves the aortic root and travels to the periphery, where smaller arterioles provide multiple points of reflection. A resulting 'reflective' wave is generated and returns to central arteries ([@b102]). In individuals with healthy compliant arteries, the reflective wave will return to the central vasculature in diastole and augment diastolic coronary arterial blood flow. The speed of the advancing wave is termed pulse wave velocity (PWV) ([@b71]). With age, a combination of increased reflective capacity at peripheral sites and faster PWV within stiffened vessels causes premature augmentation of the systolic waveform, forming a 'late systolic peak' on waveform analysis ([Figure 1](#fig1){ref-type="fig"}). This explains the differences between the brachial and aortic pressure waveforms, which may be as high as 20 mmHg ([@b105]). The central pressure waveform is important in view of determining left ventricular workload, which is relatively independent of the brachial pressure.
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In view of the above observations, a technique has been derived by [@b101], which is able to noninvasively record the peripheral pulse pressure wave and generate a corresponding central arterial waveform. The technique involves the use of an applanation tonometer to record the radial pulse wave. Applanation tonometry causes partial flattening of the arterial wall and equilibration of intra-arterial circumferential pressure. The accuracy of arterial tonometry in recording peripheral waveforms has been described by previous investigators who evaluated waveforms derived from noninvasive tonometry and direct arterial puncture ([@b26]). The central arterial waveform can subsequently be derived from the peripheral waveform using a validated generalized transfer factor ([@b61]; [@b22]; [@b127]; [@b36]). This is then expressed in terms of an Augmentation Index (AIx) which can be used to assess vascular stiffness and cardiovascular risk between study groups.

Pulse wave analysis has more recently been used as a noninvasive tool to assess endothelial function ([@b152]). Administration of β-agonist therapy induces repeatable reductions in the AIx, which are inhibited by infusion of L-N^G^-monomethyl arginine (L-NMMA), suggesting that observed differences are endothelial- and NO-dependent ([@b152]). Nitroglycerin administration induces further reductions in the AIx which are unaffected by L-NMMA and thus endothelial-independent ([@b152]). Furthermore, the technique has been shown to correlate with FMD in healthy and type 2 diabetic subjects ([@b157]).

The analysis of PWV uses a similar system that calculates pulse wave propagation velocity between two sites, commonly the carotid and femoral pulses, or carotid and radial ([@b100]), although brachial-ankle PWV has been assessed by some ([@b62]; [@b55]). Pulse wave velocity is inversely proportional to vessel stiffness and distensibility ([@b94]). Waveform data is recorded from two sites using noninvasive tonometry and stored electronically. Following documentation of the distance between the two recording sites, determination of the pulse transit time allows calculation of PWV. In order to assess pulse transit time a correlation point is identified within the pressure waveform, which may be the foot of the pressure wave (using SphygmoCor system) or the point of maximal upstroke (using Complior system) ([@b88]). If the two pressure waveforms are not recorded simultaneously, an R wave on the electrocardiograph can be used to calculate wave transit time. Elevation of PWV leads to augmentation of the ascending aortic systolic waveform as previously outlined, resulting in higher left ventricular afterload and amplification of pulse pressure ([@b92]).

Pulse wave analysis and PWV are both noninvasive simple techniques that can be used to assess vascular stiffness in research and clinical settings ([@b101]; [@b48]; [@b125]). Both techniques are influenced by factors that may confound data. For example, elevation in pulse rate will lower the AIx as a result of a reduction in reflective wave amplitude, and does not represent a change in vascular stiffness ([@b155]). Consequently, a correction factor has been suggested to standardize for variation in heart rate ([@b153]). In addition, an inverse relationship between AIx, PWV, and height has been described, which may result from shorter reflective wave propagation time in individuals with short stature ([@b82]). While some investigators consider this a confounding variable in data analysis, it may explain the elevation in cardiovascular risk observed in short individuals ([@b59]). Despite the lack of data to confirm correlation between noninvasive and invasive measurements of PWV ([@b23]; [@b30]), the evidence that tonometer-derived PWV is an important determinant of cardiovascular risk is difficult to dispute.

### Association with coronary artery disease and atherosclerotic risk factors

Pulse wave analysis has revealed accelerated large artery stiffening and endothelial dysfunction in association with several well established cardiovascular risk factors such as obesity ([@b124]), end-stage renal failure ([@b27]), and hypercholesterolemia ([@b156]). Similarly, PWV is increased in microalbuminuria ([@b121]), renal dysfunction ([@b47]), type 2 diabetes ([@b135]), and insulin resistance ([@b118]).

Using PWA and PWV, vascular stiffness has been assessed and identified as an independent risk marker for cardiovascular mortality ([@b69]; [@b86]) and cerebrovascular events ([@b68]), and has a prognostic value equivalent to currently available biomarkers.

Elevations of central systolic pressure and consequent proatherosclerotic effects can be modified by vasodilatory compounds which reduce PWV in peripheral vessels without altering brachial blood pressure. Such reductions in augmentation of central pressure may underlie the observed benefits of cardiovascular drugs which are not currently attributed to blood pressure modification ([@b92]). Vascular stiffness has consequently gained increasing importance as a therapeutic target.

Photophlesymographic assessment of pulse wave reflection
--------------------------------------------------------

### Method of assessment

Photophlethysmography involves measuring the digital volume pulse via infrared light transmission through the finger. Previous investigators have demonstrated that the digital volume pulse resembles the carotid pressure wave and alters in a similar way to vasoactive mediators ([@b127]). Reflected peripheral waveforms cause a second peak in the digital volume pulse (DVP) in a similar fashion to that seen in the peripheral pressure waveform, as measured using PWA ([@b24]). With this technique, the point at which the reflective wave meets the systolic waveform is termed the inflection point (IP). When suprasystolic pressure is applied to both lower limbs at thigh level, the reflective wave returns sooner and causes an expected elevation of the IP ([@b24]). In a similar way to the peripheral pressure wave, the DVP undergoes changes in response to exogenous NO donors such as GTN ([@b90]; [@b75]), which is independent of changes in heart rate ([@b24]). Using both techniques, the major change seen is a reduction in the diastolic component of the waveform and the preceding IP ([@b24]). This has been demonstrated recently in vivo, where acetylcholine-induced endothelial-derived NO release resulted in lowering of the IP in the photophlethysmographic waveform recorded in cholesterol-fed rabbits. This response is diminished in cholesterol-fed rabbits when compared with healthy rabbits and antagonised by NOS inhibitors ([@b63]). As with PWA, pharmacological preparations which induce NO release, such as β-adrenergic drugs, will also cause a reduction in the IP of the pulse volume waveform ([@b24]). Such effects are blunted by L-NMMA administration which suggests that this effect involves the L-arginine-NO pathway ([@b24]).

### Association with coronary artery disease and atherosclerotic risk factors

With evidence supporting the use of this technique to assess both endothelial-dependent and endothelial-independent vasodilatation, investigators have studied patient groups who are known to demonstrate marked endothelial dysfunction. Photophlethysmographic examination of type 2 diabetics has shown impairment of albuterol-induced responses with preservation of the endothelial-independent vasodilatation seen with GTN ([@b24]). Vascular stiffness using this technique has also been described in cases of impaired glucose tolerance ([@b98]) and hypertension in aging individuals, although some authors believe the technique to be inferior to PWV ([@b14]). However, this noninvasive technique provides a useful method of assessing vascular stiffening, in which both endothelial-dependent and independent responses can be determined ([@b89]).

Biomarkers of endothelial function
==================================

As outlined previously, the antiatherogenic functions of the endothelium are complex. Several biochemical markers have been identified that correlate with coronary artery disease and conventional cardiovascular risk factors ([@b126]). Further investigation of the inflammatory and thrombotic processes involved in atherogenesis will allow the assessment of potential biomarkers which may be incorporated into current cardiovascular risk stratification models. Such biomarkers include, oxidized low-density lipoprotein (oxLDL), high sensitivity C-reactive protein (CRP), endothelial progenitor cells (EPC), prothrombotic factors such as von Willebrand factor (VWF), and inflammatory markers including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and intracellular adhesion molecule-1 (ICAM-1) ([@b111]; [@b126]). The clinical use of many of the biomarkers is restricted due to lack of end-point data ([@b134]), with the exception of CRP which may correlate to a greater extent than traditional risk factors such as LDL-cholesterol ([@b109]). In consequence, CRP has already been incorporated into some risk stratification models.

Oxidized LDL
------------

Oxidation of LDL occurs within the subendothelial cells of the vascular tissue which promotes the binding and transformation of monocytes to foam cells ([@b104]; [@b145]). Mechanisms include enhancing chemotaxis and monocyte adhesion, upregulation of inflammatory genes and growth factors, causing endothelial cell dysfunction and apoptosis, enhancing platelet aggregation with thrombus formation, and inducing plaque destabilisation ([@b12]; [@b1]; [@b97]). Consequently, oxLDL levels are increased in cases of acute coronary syndrome and myocardial infarction ([@b133]).

Prothrombotic factors
---------------------

The prerequisites for thrombogenesis in atheromatous plaques include activation of the coagulation cascade and platelet activation ([@b123]). As such, prothrombotic factors are often evaluated in studies aimed at assessing cardiovascular risk. von Willebrand factor is a multimeric glycoprotein that is synthesised in endothelial cells and released following endothelial damage ([@b78]). As such, levels can be indicative of the degree of endothelial injury and subsequent atherosclerotic potential ([@b78]). Prospective trials suggest that elevated VWF may predict future cardiovascular events in patients with established coronary atherosclerosis ([@b58]; [@b130]), which may be a reflection of the role of VWF in initiating platelet aggregation and thrombus formation ([@b78]). von Willebrand factor also has a role in stabilising factor VIII and the latter, together with fibrinogen, have been incorporated into cardiovascular risk profiles in numerous studies ([@b149]; [@b37]; [@b20]; [@b21]).

Endothelial progenitor cells
----------------------------

Endothelial progenitor cells have also gained importance as a potential surrogate marker of endothelial health ([@b117]). These are essentially stem cells which are recruited to sites of endothelial injury in order to perform a therapeutic function by differentiating into mature endothelial cells ([@b126]). Depletion of circulating EPCs with impaired adhesion to vasculature may reflect repeated and enhanced demand for EPC mobilization from bone marrow, and indicate a state of endothelial dysfunction predisposing to enhanced cardiovascular risk ([@b50]). In support of this, reduced EPC levels with impaired activity have been demonstrated in subjects known to have impaired endothelial function, such as hypertension and ischemic heart disease ([@b138]) and their use for therapeutic intervention of vascular dysfunction continues to be evaluated ([@b120]).

Inflammatory markers
--------------------

Several inflammatory markers have been described in association with cardiovascular risk, including TNF-α, IL-6, ICAM-1, and CRP, of which CRP has greatest prognostic value ([@b111]; [@b110]). CRP is not only a marker of cardiovascular risk, but may itself function as a proatherogenic molecule ([@b126]). The acute phase reactant has been demonstrated to enhance proinflammatory cytokines, such as IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1), promoting chemotaxis and lipid accumulation ([@b141]; [@b73]). In addition, CRP may interfere with NO synthesis, inhibit angiogenesis, and influence vascular remodelling ([@b140]; [@b146]). Although CRP correlates well with atherogenesis, it is feasible that elevation reflects the impact of traditional risk factors on inflammatory processes, as opposed to the direct influence of CRP on endothelial function ([@b142]; [@b139]).

Summary
=======

As the number of individuals suffering from the 'metabolic syndrome' escalates, the cardiovascular morbidity and mortality rates of future generations may continue to rise despite advances in pharmaceutical interventions. Disruption of endothelial function is multifactorial and complex, and precedes clinically apparent coronary and cerebrovascular disease.

Therefore, the evaluation of reproducible, noninvasive techniques for assessing endothelial function should enable screening of large populations and may guide interventions designed specifically to reduce the individual\'s vascular risk.
